Introduction
============

Diabetes mellitus (DM) has become a major public health problem worldwide ([@b1-etm-0-0-6769]). It is a major risk factor for ischemic heart disease and stroke, chronic kidney disease and blindness, and is responsible for high rates of morbidity and mortality among patients ([@b2-etm-0-0-6769]--[@b4-etm-0-0-6769]). Type 1 (T1) DM is characterized as a chronic autoimmune disease of the pancreas, causing progressive destruction of β-cells ([@b5-etm-0-0-6769]). Patients with T1DM eventually require exogenous insulin to control their blood glucose. Regarding the treatment of DM patients, various methods have been evaluated, including the use of cytostatic drugs ([@b6-etm-0-0-6769],[@b7-etm-0-0-6769]), monoclonal antibodies (e.g. rituximab, teplizumab) ([@b8-etm-0-0-6769],[@b9-etm-0-0-6769]) and vaccines for modifying the patient\'s abnormal immune system response ([@b10-etm-0-0-6769]). Transplantation of the entire human pancreas or isolated, cadaveric human islets, which has provided proof of concept for β-cell replacement therapies, has made T1DM patients insulin-independent ([@b11-etm-0-0-6769],[@b12-etm-0-0-6769]). However, the transplantation mentioned above has remained to be fully developed and effectively implemented in clinical practice. The major limitations include surgery-associated complications, the requirement of donor cells ([@b13-etm-0-0-6769]) and immunosuppressants ([@b14-etm-0-0-6769]), and the risk of immune rejection ([@b15-etm-0-0-6769]) and recurrence ([@b16-etm-0-0-6769]).

Stem cell (SC) transplantation has emerged as a breakthrough treatment due to of the intrinsic regenerative capacity and immunomodulatory properties of SCs ([@b17-etm-0-0-6769]), which may achieve arrest of autoimmune β-cell destruction and generate functional β-cells ([@b18-etm-0-0-6769]). SC therapy may represent a novel paradigm for optimizing glycemic control in T1DM. Meta-analyses of studies on SC therapy for liver cirrhosis ([@b19-etm-0-0-6769]), chronic liver disease ([@b20-etm-0-0-6769]), inflammatory bowel disease ([@b21-etm-0-0-6769]) and ischemic heart disease ([@b22-etm-0-0-6769]) have indicated a certain potential for cell therapy-based strategies. In animal studies, it was demonstrated that SCs are able to relieve hyperglycemia by differentiating into insulin-producing cells, thereby promoting the transformation of α-cells to β-cells, improving pancreatic regeneration and ameliorating insulin resistance. In the present meta-analysis, the efficacy and safety of SC therapy for the treatment of patients with T1DM was assessed based on published and unpublished clinical trials. Representative outcome data were analyzed, including the mean values of C-peptide levels, glycated hemoglobin (HbA1c) levels, fasting plasma glucose (FPG) and daily insulin requirement every three months over 12 months.

C-peptide, a connecting peptide, is a short 31-amino-acid polypeptide that connects the A-chain of insulin to its B-chain in the pro-insulin molecule. In diabetes, measurement of C-peptide blood serum levels may be performed to distinguish between certain diseases with similar clinical features ([@b23-etm-0-0-6769]). HbA1c may be assessed to evaluate the average blood sugar levels over a period of weeks/months ([@b24-etm-0-0-6769]). For patients with diabetes, this is important, as higher HbA1c levels are linked with a greater risk of developing diabetes-associated complications. A fasting plasma glucose (FPG) test, a simple blood test taken after several h of fasting, also known as the fasting glucose test, may be used to diagnose diabetes or pre-diabetes ([@b25-etm-0-0-6769]). The insulin requirement reflects the degree of insulin dependence in diabetic patients. In the present study, two major subgroup analyses \[data from randomized-controlled trials (RCTs) and self-controlled trials (SCTs)\] were performed. Several subgroups were classified based on the origin and nature of SCs within each major group, including hematopoietic stem cells (HSC), mesenchymal stem cells (MSC) and umbilical cord blood (UCB). The RCTs reflected the efficacy of a population-based study, while that of individuals was demonstrated by the SCTs. In these two major groups, the present study aimed to explore the therapeutic efficacy of different SCs in patients with T1DM.

Materials and methods
=====================

### Guidelines and data availability

This systematic review was registered at the International prospective register of systematic reviews (no. 42018093930). Study inclusion and exclusion was performed in accordance with the Preferred Reporting Items for Systematic reviews and Meta Analyses ([@b26-etm-0-0-6769]) and the Cochrane handbook for systematic reviews of interventions ([@b27-etm-0-0-6769]).

### Literature search

A systematic search of studies published from inception until 13th January 2018 was performed in the databases PubMed (<https://www.ncbi.nlm.nih.gov/pubmed>), MEDLINE (<https://www.medline.com/home.jsp>), WanFang (<http://g.wanfangdata.com.cn/index.html>) and the Cochrane Library (including CENTRAL; <http://www.cochranelibrary.com/>). To accurately identify clinical trials of SC transplantation in T1DM patients, a search was performed using a combination of Me-SH terms and text words: ('type 1 diabetes' OR 'diabetes mellitus type 1' OR 'hyperglycemia') AND ('stem cells' OR 'progenitor cells' OR 'mesenchymal stem cell' OR 'mononuclear stem cell' OR 'hematopoietic stem cell' OR 'progenitor cell' OR 'beta cell') AND ('cell therapy' OR 'treated' OR 'therapeutic' OR 'treatment'). No language restrictions were applied. Furthermore, potentially eligible studies were identified by screening the lists of references of the retrieved articles as well as in review articles and abstracts from relevant conferences. The most recent or complete studies were selected for analysis when the same or similar patient data were included. Furthermore, information of prospective and ongoing trials was retrieved from <http://www.ClinicalTrials.gov>, a database created to establish a registry of clinical trials involving investigational drugs as a result of the Food and Drug Administration Modernization Act of 1997 and a Final Rule issued by Department of Health and Human Services ([@b28-etm-0-0-6769]). All of the searches were performed by two investigators independently (GJD and WYJ).

### Study selection

The following inclusion criteria were applied to select studies based on their titles and abstracts: i) The studies were clinical trials, but not pre-clinical trials, reviews, comments, case reports or basic scientific research; ii) the subjects included had been diagnosed with T1DM; iii) the participants received SC therapy (no restriction was applied regarding the source and route of administration of the stem cells). Studies were excluded if: i) They were animal studies; ii) the included participants did not undergo SC therapy; iii) they contained duplicate data; iv) the C-peptide levels, HbA1c levels and FPG or insulin requirement assessed every 3 months over a 12 month period were not included and could not be calculated from the data.

Furthermore, when the data overlapped or were duplicated between two or more studies by the same group, the most recent study, which contained more complete data were included. The articles were independently evaluated by two reviewers (GJD and WYJ) in duplicate and selected for inclusion if they met the abovementioned criteria. Discrepancies were resolved by consensus.

### Data extraction and quality assessment

Primary items were independently extracted by two authors (GJD and WYJ), including the request for documentation and recalculation of the following variables, through a standardized data collection form. The form included: a) The first author\'s name, b) year of publication, c) country, d) size of study population, e) study design, f) mean age, g) gender of the participants, h) history of DM, i) type of SCs, j) mean dose of injected cells, k) path of injection, l) follow-up time, m) C-peptide levels, n) HbA1c levels, o) FPG and p) insulin requirement was assessed every 3 months over 12 months. The data for C-peptide levels, HbA1c levels and FPG were extracted to identify changes over time and evaluate the length of SC treatment. For continuous outcomes, the mean, standard deviation and total sample size were recorded. Furthermore, the corresponding authors of studies with insufficient data or studies that could not be located were contacted by email and asked whether they were willing to share their unpublished data from these trials for inclusion in the present analysis. If no reply was received, the study was excluded from the meta-analysis. Those data that were the outcomes of interest of the present study were pooled with the data from the primary trials.

Data from SCTs were analyzed to evaluate whether the SC therapy improved the symptoms of patients with T1DM. The data from RCTs were pooled to evaluate whether the SC therapy was superior to the standard or conventional therapy in improving the symptoms of T1DM patients.

Two reviewers (GJD and WYJ) independently assessed the methodological quality of the nine RCTs by rating them on the Jadad scale ([@b29-etm-0-0-6769]). The quality scale of Jadad ranges from 0 to 5 points, with a score of ≤2 indicating a low-quality study and a score of ≥3 indicating a high-quality study. Disagreements were resolved by discussion between the two reviewers.

### Statistical analysis

Meta-analysis was performed with a random-effects model (DerSimonian-Laird method) by using Stata 14.0 (StataCorp LP, College Station, TX, USA). The standardized mean difference (SMD) was used to combine treatment effect data. A random-effects model was used to compute the pooled standardized mean deviation of C-peptide and HbA1c levels with 95% confidence intervals (CI), as this model takes into account any differences between studies even if there is no statistically significant heterogeneity ([@b27-etm-0-0-6769]). The heterogeneity among the studies was assessed using the inconsistency index (I^2^) statistics ([@b30-etm-0-0-6769],[@b31-etm-0-0-6769]) \[I^2^ describes the percentage of total variation across studies that are due to heterogeneity rather than to chance and I^2^\>50% was considered to indicate substantial heterogeneity based on the suggestion in the Cochrane Handbook for Systemic Reviews of Interventions ([@b27-etm-0-0-6769])\] and the Chi-square test (the risk of random error is the risk of drawing a false conclusion based on sparse data). This risk is quantified as the P-value, and P\<0.05 was considered to indicate significant statistical heterogeneity.

To determine the primary outcomes, Egger\'s test was employed to assess the publication bias ([@b32-etm-0-0-6769]). Clinical heterogeneity was assessed by subgroup analysis with patients stratified according to age, medical history and cell dose. Prespecified subgroup analyses were performed to explore potential heterogeneity between subgroups (P\<0.05 was considered to indicate significant statistical heterogeneity). To evaluate whether the association between C-peptide levels or HbA1c levels and SC therapy was affected by clinical characteristics, the subjects were stratified into subgroups based on age (\<18 or ≥18 years), medical history (\<3 or ≥3 months) and cell dose (\<10^7^ or ≥10^7^ IU/kg/day). Data were analyzed using Stata statistical software version 14.0 (StataCorp LP).

Results
=======

### Literature search and study selection

The literature search performed in the present study yielded 2,023 records of potentially eligible studies, of which 674 were excluded due to being duplicates. Following screening of titles and abstracts of the remaining 1,349 studies, a total of 1,302 studies were excluded based on the inclusion and exclusion criteria, among which 27 were reviews, 57 were case reports, 68 included animal studies and 1,150 were irrelevant. Finally, 47 full-text articles were considered for inclusion, among which 22 included original research papers ([@b33-etm-0-0-6769]--[@b54-etm-0-0-6769]). A flowchart illustrating the selection process is presented in [Fig. 1](#f1-etm-0-0-6769){ref-type="fig"}.

### Study and patient characteristics

A total of 9 RCTs and 14 SCTs were included in the final meta-analysis. Their details are summarized in [Table I](#tI-etm-0-0-6769){ref-type="table"}. Of the studies, 2 were published prior to 2009 and 19 were published from 2010 onwards. The eligible studies represented an international population, as they were performed in a large range of countries, including China, India, Poland, Spain, USA, Sweden, Argentina, Germany and Brazil, with the age of participants ranging from 3 to 40 years. Individual patient data were obtained for 455 participants, including 189 from the RCTs and 266 from SCTs. The length of follow-up period ranged between 1 and 12 months. The most common injection route of the SCs in the studies included was intravenous. Thakkar *et al* ([@b34-etm-0-0-6769]) and Vanikar *et al* ([@b50-etm-0-0-6769]) used intra-pancreatic injection. Furthermore, Cai *et al* ([@b37-etm-0-0-6769]) used a pancreatic artery cannulation method.

### Quality assessment

A total of 9 RCTs included a control group (placebo or hypoglycemic agent) in a double-blinded design. Through Jadad score tools, 5 studies \[Cai *et al* ([@b37-etm-0-0-6769]), Carlsson *et al* ([@b40-etm-0-0-6769]), Hu *et al* ([@b41-etm-0-0-6769]), Haller *et al* ([@b42-etm-0-0-6769]) and Yu *et al* ([@b46-etm-0-0-6769])\] received 5 points, one study \[Zhao *et al* ([@b43-etm-0-0-6769])\] received 4 points and one study \[Ye *et al* ([@b33-etm-0-0-6769])\] received 3 points. These eight studies were considered to be of high quality, whereas another study \[Giannopoulou *et al* ([@b38-etm-0-0-6769])\] received 2 points and was considered a low-quality study ([Fig. 2](#f2-etm-0-0-6769){ref-type="fig"}). In addition, 13 studies were designed as SCTs, for which no approved assessment tools were available to evaluate the SCTs. However, these studies were also repeatedly reviewed and quality assessments were performed. Each of these SCTs included detailed selection procedures, strict descriptions of the procedures and an adequate follow-up period.

### Publication bias

Begg\'s funnel plot revealed no evidence of publication bias for the outcomes examined (P\>0.05; [Fig. 3](#f3-etm-0-0-6769){ref-type="fig"}). This indicated that the present results may slightly overestimate the true effect size if non-significant studies are not identified. The potential publication bias of the effects of SC therapy on C-peptide and HbA1c estimated in RCTs ([Fig. 3A and B](#f3-etm-0-0-6769){ref-type="fig"}). The potential publication bias of the effects of SC therapy on C-peptide and HbA1c estimated in SCTs ([Fig. 3C and D](#f3-etm-0-0-6769){ref-type="fig"}).

### Efficacy of SC treatment in RCTs

Compared with conventional insulin therapy, SC treatment resulted in a statistically significant difference in the increase of C-peptide levels in T1DM patients with an overall SMD of 0.93 (95% CI, 0.23--1.63; I^2^=74.4%; P=0.009). As presented in [Fig. 4](#f4-etm-0-0-6769){ref-type="fig"}, a statistically significant pooled effect was determined in the HSC group (SMD, 0.92; 95% CI, 0.09--1.74; I^2^=0.0%; P=0.029) and in the MSC group (SMD, 0.53; 95% CI, 0.00--1.05; I^2^=0.0%; P=0.048), whereas in the UCB group, no statistically significant effect was observed (SMD, 0.31; 95% CI, −0.41 to 1.04; I^2^=0.0%; P=0.397). The data obtained by Cai *et al* ([@b37-etm-0-0-6769]) indicated a significant efficacy of MSC+HSC (SMD, 3.00; 95% CI, 2.11--3.89). At the same time, the pooled effect of HbA1c reduction was significantly different from that in the insulin treatment group (the control group) with an overall SMD of 0.56 (95% CI, 0.06--1.06; I^2^=51.4%; P=0.028; [Fig. 5](#f5-etm-0-0-6769){ref-type="fig"}). Furthermore, MSC+HSC exerted a decent therapeutic effect on T1DM patients in terms of HbA1c with an SMD of 0.67 (95% CI, 0.05--1.29; P=0.034). However, the effect in the groups treated with HSC (SMD, −0.07; 95% CI, −1.00 to 0.86; P=0.089), UCB (SMD, 0.82; 95% CI, −0.88 to 2.52; I^2^=78.2%; P=0.345) and MSC (0.62; 95% CI, −0.32 to 1.55; I^2^=65.1%; P=0.197) overlapped with the no effect lines, indicating that the differences in these groups were not statistically significant.

### Efficacy of SC therapy in SCTs

The overall meta-analyses of data from SCTs are presented in [Figs. 6](#f6-etm-0-0-6769){ref-type="fig"} and [7](#f7-etm-0-0-6769){ref-type="fig"}. The results indicated that SC treatment significantly increased C-peptide levels after 12 months in the HSC group (SMD, 1.72; 95% CI, 0.47--2.97; I^2^=95.1%; P=0.007), the MSC group (SMD, 0.61; 95% CI, 0.09--1.13; I^2^=0.0%; P=0.021) and the MSC+HSC group (SMD, 1.83; 95% CI, 0.41--3.25; I^2^=85.5%; P=0.011). On the contrary, the results obtained using UCB suggested that SC therapy reduced C-peptide levels (SMD, −1.97; 95% CI, −3.30 to −0.63; I^2^=87.5%; P=0.004); however, Zhao *et al* ([@b43-etm-0-0-6769]) reported a decent curative effect with UCB-SC therapy (SMD, 1.82; 95% CI, 0.44--3.21; P=0.010). It was therefore apparent that UCB-SC therapy had a different effect when compared with that of treatment with UCB.

The analysis of changes in HAb1c levels demonstrated that SC therapy resulted in a statistically significant difference from the control group after 12 months in the groups treated with HSC (SMD, 2.74; 95% CI, 1.38--4.09; I^2^=95.7%; P\<0.001), MSC (SMD, 1.71; 95% CI, 0.25--3.16; I^2^=78.7%; P=0.022) and MSC+HSC (SMD, 1.02; 95% CI, 0.57--1.48; I^2^=0.0%; P\<0.001). Similar to the result regarding the C-peptide levels, UCB treatment did not significantly reduce the HbA1c levels (SMD, 0.06; 95% CI, −0.45 to 0.57; I^2^=46.0%; P=0,831).

### FPG and insulin requirement

In two RCTs \[Ye *et al* ([@b33-etm-0-0-6769]) and Yu *et al* ([@b47-etm-0-0-6769])\], the FPG level (mmol/l) was reported at the 12-month follow-up time-point. The pooled effect of FPG reduction at 12 months after SC treatment achieved an SMD of 0.86 (95% CI, 0.13--1.60; P=0.021), whereas in the control group, no significant difference was identified with insulin treatment (SMD, 0.38; 95% CI, −0.37 to 1.13; P=0.323; [Fig. 8](#f8-etm-0-0-6769){ref-type="fig"}) compared with baseline. The results demonstrated that SC therapy is an efficient option while insulin may not.

[Figs. 9](#f9-etm-0-0-6769){ref-type="fig"}--[11](#f11-etm-0-0-6769){ref-type="fig"} present the trend of insulin requirement after treatment. The insulin requirement vs. time curves exhibited a downward trend, demonstrating that SC transplantation resulted in a reduction in exogenous insulin requirement in patients with T1DM.

### Subgroup analysis

A subgroup analysis was performed to assess the influence of clinical characteristics and the type of SCs on the therapeutic effect compared with the insulin-treated control group. As presented in [Table IIA](#tII-etm-0-0-6769){ref-type="table"}, an age of ≥18 years and a disease history of \<3 months were associated with a greater increase in C-peptide levels in patients transplanted with HSC (P\<0.001), whereas in patients treated with MSC+HSC, an age of \<18 years and a cell dose of ≥10^7^ IU/kg/day was associated with higher C-peptide levels. The subgroup analysis also indicated that patient age, disease history and the dose of SCs used led to different results in patients treated with UCB. However, UCB therapy was not recommended since it had a worse outcome compared with the other treatments. No significant differences were identified in patients transplanted with MSC.

As presented in [Table IIB](#tII-etm-0-0-6769){ref-type="table"}, regarding the change in HbA1c levels at the 12-month follow-up, statistically significant differences in the effect of HSC treatment were identified in patients of different age and disease history subgroups (an age of ≥18 years and a disease history of \<3 months were associated with lower HbA1c levels). Furthermore, an SC dose of ≥10^7^ IU/kg/day was associated with lower HbA1c levels in patients with MSC therapy, which demonstrated SC therapy at the aforementioned dose was more efficient. Regarding UCB therapy, a significant difference between dose groups was identified. Regarding UCB therapy, a significant difference between the two dose groups was identified, but the treatment did not significantly improve the overall outcome. No statistically significant differences were identified for any of the other comparisons.

Discussion
==========

In recent years, significant progress has been made regarding the treatment of diabetes. With the development of genomics, genetics, cell biology, and other major advances in science and technology, a major breakthrough has emerged in the treatment of diabetes ([@b55-etm-0-0-6769],[@b56-etm-0-0-6769]). The present systematic review and meta-analysis suggested that SC therapy has a potential therapeutic effect in T1DM patients.

As presented by the pooled effect of RCTs, HSC, MSC and MSC+HSC therapy resulted in a higher C-peptide level increase when compared with that achieved by conventional insulin treatment, whereas UCB did not. The higher C-peptide levels significantly proved the regeneration of β-cell function after SC therapy. As for the reduction of HbA1c levels, MSC+HSC had a significantly better efficacy when compared to insulin and MSC treatment resulted in a similar trend. However, the results did not support that HSC and UCB had a better effect on the regulation of HbA1c levels when compared to insulin, with the reduction in HbA1c indirectly representing the degree of glycemic control.

As indicated by the pooled effect of SCTs, HSC, MSC and MSC+HSC all had a significant effect on the C-peptide increase after 12 months, compared to the baseline level. These results indicated that these three methods all improved β-cell function. In addition, UCB treatment had an opposite effect to that of and UCB-SC: UCB-SC was effective, whereas UCB was not or even resulted in a worse outcome. This result demonstrated that the dose of SCs may affect the effect of SC therapy, which may result from the variation of SCs volume between UCB and UCB-SC. Similar results were obtained regarding the reduction of HbA1c levels. HSC, MSC and MSC+HSC all reduced the HbA1c levels over a period of 12 months after SC transplantation, whereas the UCB was not effective.

Given that the present analysis was obtained from measurements every three months the results may have some deviation, since the measurement of HbA1c is slightly delayed in the diagnosis of hyperglycemia ([@b57-etm-0-0-6769]). In addition, C-peptide levels have a moderate capacity to reflect the regeneration of β-cell function.

Based on the results of the subgroup analysis, it may be concluded that the group aged ≥18 years and patients with a medical history of \<3 months benefited significantly more from HSC transplantation. An SC injection dose of ≥10^7^ IU/kg/day may be more suitable when MSC+HSC therapy is employed in patients aged ≥18 years with a recent (\<3 months) diagnosis of DM.

At present, methods for SC therapy are limited by certain bottlenecks. To implement novel cell therapy-based strategies in the clinic, numerous issues require addressing. For instance, the mechanism for the differentiation of SCs into islet β-cells remains to be fully elucidated, reproducible induction methods require to be established and there is no consensus regarding the definitive functional criteria for induced cells. Therefore, it is challenging to determine whether the obtained cells are suitable for replacing the islet β-cells. Furthermore, the number of implanted SCs, the site of transplantation, the host\'s immune response after transplantation and carcinogenicity are all issues that require addressing by future studies. In a previous study, only few of the pediatric T1DM patients treated by autologous umbilical cord blood transfusion no longer required insulin ([@b58-etm-0-0-6769]). Thus, the major function of β-cells, namely robust glucose-induced insulin secretion, may not be easily realized by SCs. The combination of multiple approaches and methods may be the safest and most effective type of immunomodulatory therapy.

One issue that must be considered is the safety of SC therapy. Besides the immune reaction mentioned above, Gu *et al* ([@b46-etm-0-0-6769]) demonstrated that patients experienced different degrees of gastrointestinal reactions, hair loss, fever, bone marrow suppression and other adverse reactions during the process of transplantation. Fortunately, no significant organ, heart, liver or kidney dysfunction was observed and adverse reactions gradually disappeared at 2--4 weeks after SC reinfusion.

Furthermore, a major safety issue exists regarding the numerous rounds of replication that these SCs undergo prior to transplantation into the patient, which may result in the accumulation of chromosomal abnormalities and the cells may eventually become malignant.

The analysis of the present study has several strengths. Firstly, the robust methodology is a major strength. It was attempted to consider all available published studies via searching four major databases, and the data quality was assessed and to obtain suitable data. Furthermore, no language restrictions were imposed on the articles included. In addition, the present study compared data between SC therapy and conventional insulin treatment groups, and also included data from prior to and after SC therapy, which not only indicated the individuality of the treatments, but also reflected their applicability. In the present analysis, a random-effects model was employed, which was able to correlate individual observations to fit non-independent observation data. In addition, subgroup analyses were performed to confirm the consistency of conclusions among the different subgroup populations.

Several limitations of the present analysis reduce the value of the information obtained. First, in several trials included, the baseline C-peptide levels, HbA1c levels and FPG concentrations of participants were not assessed. Therefore, results of the subgroup analyses may have been different if all of the indexes had been assessed. Furthermore, several of the studies included \[Ye *et al* ([@b33-etm-0-0-6769]), Giannopoulou *et al* ([@b38-etm-0-0-6769]) and Zhao ([@b43-etm-0-0-6769])\] were of poor quality, e.g. due to using unclear allocation concealment. In addition, there was a lack of original trials and the sample size of the studies included was limited. Finally, one inevitable limitation of the present study was the heterogeneity between the studies, which was based on differences between the institutions from various parts of the world.

In conclusion, according to the present meta-analysis, the use of SCs, including HSC, MSC or MSC+HSC, may be considered an effective approach for the therapy of T1DM. These results supported the routine application of these therapies in patients with T1DM. The use of USB is not recommended; however, a USB-SC component may be considered. Furthermore, patients aged ≥18 years or with a duration of T1DM of \<3 months demonstrated a greater benefit from HSC transplantation. A SC injection dose of ≥10^7^ IU/kg/day is more suitable in patients undergoing MSC+HS transplantation. Taken together, the present results may guide the further development of SC therapy and its implementation in the clinic, and indicate that SC therapy holds great promise for treating T1DM. In the future, additional trials are required to further elucidate the subject.
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###### 

Characteristics of the trials included.

  First author (year)   Country   Cases/Total   Design   Mean age (years)   Gender (F/M)   BMI (kg/m^2^)   History of DM   Intervention   Dose           Injection path   Time to follow-up (months)   (Refs.)
  --------------------- --------- ------------- -------- ------------------ -------------- --------------- --------------- -------------- -------------- ---------------- ---------------------------- -----------------------
  Ye (2017)             China     10/18         RCT      18.9±1.5           6/4            19.2 ± 1.1      \<6 months      HSC              2.00×105     IV               12                           ([@b33-etm-0-0-6769])
                                  8/18                   20.2±4.0           5/3            18.2±1.3        \<6 months      Insulin                                                                     
  Thakkar (2015)        India     10/20         RCT      20.2               1/9            NA              8.1 years       MSC+HSC          2.07×10^4^   IP               3,6,9,12,24                  ([@b34-etm-0-0-6769])
                                  10/20                  19.7               4/6            NA              8.1 years       Insulin                                                                     
  Snarski (2016)        Poland    20            SCT      24.3±4.5           5/15           22.2±2.3        NA              HSC              3.0×106      IV               3,6,12,24                    ([@b35-etm-0-0-6769])
  Delgado (2015)        Spain     6/15          SCT        33.8±10.9        2/4                            6.5 years       UCB              1.0×10^6^    IV               12                           ([@b36-etm-0-0-6769])
  Cai (2016)            USA       21/42         RCT      18.3               12/9           22.0            9.2 years       MSC+HSC        106.8×106      IP               3,6,9,12                     ([@b37-etm-0-0-6769])
                                  21/42                  20.4               10/11          22.1            7 years         Insulin                                                                     
  Giannopoulou          Germany   7/17          RCT      3.0                2/5            NA              \<3 months      UCB              1.27×10^6^   IV               3,6,9,12                     ([@b38-etm-0-0-6769])
  \(2014\)                        10/17                  6.6                6/4            NA              \<4 months      Insulin                                                                     
  D\'Addio (2014)       USA       65            SCT      20.4±5.5           24/41          18.1±3.1        \<3 months      HSC              5.8×106      IV               12,24                        ([@b39-etm-0-0-6769])
  Carlsson (2015)       Sweden    9/18          RCT      24±2               1/8            23.3±1.1        \<3 weeks       MSC              2.75×10^6^   IV               12                           ([@b40-etm-0-0-6769])
                                  9/18                   27±2               4/5            22.5±0.9        \<3 weeks       Insulin                                                                     
  Hu (2013)             China     15/29         RCT      17.6±8.7           6/9            20.9±3.7        New onset       MSC              2.6×107      IV               3,6,9,12,24                  ([@b41-etm-0-0-6769])
                                  14/29                  18.2±7.9           6/8            21.3±4.2        New onset       Insulin                                                                     
  Haller (2013)         USA       10/15         RCT      7.2                NA             NA              3.9 months      UCB              1.1×10^7^    IV               6,12                         ([@b42-etm-0-0-6769])
                                  5/15                   6.6                NA             NA              3.9 months      Insulin                                                                     
  Zhao (2012)           USA       6/9           RCT      30±9               4/2            NA              6 years         UCB-SC           1.0×106      IV               12                           ([@b43-etm-0-0-6769])
                                  3/9                    33±9               0/3            NA              6 years         Insulin                                                                     
  Zhang (2012)          China     9             SCT      17.5±3.5           4/5            18.5±1.5        2 years         HSC            10.49×10^6^    IV               6,12                         ([@b44-etm-0-0-6769])
  Li (2012)             China     13            SCT      14.1±4.0           3/10           18.1±2.3        New onset       HSC              4×106        IV               12                           ([@b45-etm-0-0-6769])
  Gu (2012)             China     28            SCT      18.4±4.1           9/8            19.2±1.6        3 months        HSC              1.0×10^6^    IV               12                           ([@b46-etm-0-0-6769])
  Yu (2011)             China     6/12          RCT      19.6±2.5           3/3            21.5±1.6        \<3 months      MSC              1.0×107      IV               12                           ([@b47-etm-0-0-6769])
                                  6/12                   14.8±8.1           2/4            20.0±3.4        \<3 months      Insulin                                                                     
  Haller (2011)         USA       24            SCT      5.1                NA             NA              4 months        UCB              1.88×10^7^   IV               3,6,9,12,24                  ([@b48-etm-0-0-6769])
  Feng (2011)           China     17            SCT      13.0±3.8           9/8            NA              4 months        HSC              3×106        IV               12                           ([@b49-etm-0-0-6769])
  Vanikar (2010)        India     11            SCT      21.1               4/7            NA              8.2 years       MSC+HSC          3.15×10^6^   IP               12                           ([@b50-etm-0-0-6769])
  Snarski (2011)        Poland    8             SCT      25.8               4/4            NA              2 years         HSC              4.14×106     IV               3,6                          ([@b51-etm-0-0-6769])
  Gu (2010)             China     18            SCT      18.8±4.4           12/6           NA              \<6 months      HSC            NA             IV               3,6,12                       ([@b52-etm-0-0-6769])
  Haller (2009)         USA       15            SCT      5.5                7/8            NA              4.1 months      UCB              1.5×10^7^    IV               12                           ([@b53-etm-0-0-6769])
  Couri (2009)          Brazil    23            SCT      18.4±4.6           6/17           19.7±2.2        \<3 months      HSC            10.52×106      IV               12                           ([@b54-etm-0-0-6769])

RCT, randomized controlled trial; SCT, self-controlled trial; HSC, hematopoietic stem cells; MSC, mesenchymal stem cells; UCB, umbilical cord blood; UCB-SC, umbilical cord blood-stem cells; IV, intra-venous; IP, intra-pancreatic; NA, not available; M, male; F, female; BMI, body mass index; DM, diabetes mellitus.

###### 

Subgroup analysis of C-peptide and glycated hemoglobin changes at 12-month follow-up.

  A, C-peptide                                                                
  ---------------------------- ------- --------- -------------- ------------- ---------
  HSC                          211                                            
    Age (years)                                                               
      \<18                     118     0.87      0.54, 1.20     \<0.001       \<0.001
      ≥18                      93      3.37      2.88, 3.87     \<0.001       
    Disease history (months)                                                  
      \<3                      159     1.74      1.43, 2.04     \<0.001       \<0.001
      ≥3                       52      1.31      0.71, 1.90     \<0.001       
  MSC                          30                                             
    Age (years)                                                               
      \<18                     15      0.77      0.02, 1.51     0.043         0.254
      ≥18                      15      0.46      −0.26, 1.19    0.212         
    Dose (IU/kg/day)                                                          
      \<10^7^                  9       0.60      −0.35, 1.55    0.214         0.946
      ≥107                     21      0.62      −0.01, 1.24    0.052         
  MSC+HSC                      42                                             
    Age (years)                                                               
      \<18                     21      3.00      2.11, 3.89     \<0.001       \<0.001
      ≥18                      21      1.13      0.06, 1.80     0.001         
    Dose (IU/kg/day)                                                          
      \<10^7^                  21      1.13      0.06, 1.80     0.001         \<0.001
      ≥107                     21      3.00      2.11, 3.89     \<0.001       
  UCB                          62                                             
    Age (years)                                                               
      \<18                     56      −2.21     −2.72, −1.71   \<0.001       \<0.001
      ≥18                      6       −0.18     −1.31, 0.96    0.757         
    Dose (IU/kg/day)                                                          
      \<10^7^                  13      −1.11     −2.02, −0.19   0.017         \<0.001
      ≥107                     49      −2.14     −2.67, −1.61   \<0.001       
    Disease history (months)                                                  
      \<3                      6       −2.81     −4.35, −1.28   \<0.001       \<0.001
      ≥3                       56      −1.79     −2.27, −1.31   \<0.001       
                                                                              
  **B, Glycated hemoglobin**                                                  
                                                                              
  **Variable**                 **N**   **SMD**   **95% CI**     **P-value**   
                                                                              
  HSC                          211                                            
    Age (years)                                                               
      \<18                     118     1.31      1.01, 1.61     \<0.001       \<0.001
      ≥18                      93      4.53      3.90, 5.16     \<0.001       
  Dose (IU/kg/day)                                                            
      \<10^7^                  188     1.91      1.62, 2.20     \<0.001       0.899
      ≥107                     23      1.92      1.22, 2.63     \<0.001       
    Disease history (months)                                                  
      \<3                      159     2.26      1.93, 2.59     \<0.001       \<0.001
      ≥3                       52      1.21      0.73, 1.68     \<0.001       
  MSC                          30                                             
    Age (years)                                                               
      \<18                     15      1.23      0.45, 2.02     0.007         0.947
      ≥18                      15      1.21      0.33, 2.08     0.002         
    Dose (IU/kg/day)                                                          
      \<10^7^                  9       0.63      −0.32, 1.58    0.192         0.006
      ≥107                     21      1.58      0.84, 2.32     \<0.001       
  MSC+HSC                      42                                             
    Age (years)                                                               
      \<18                     21      0.97      0.33, 1.62     0.001         0.616
      ≥18                      21      1.07      0.42, 1.73     0.003         
    Dose (IU/kg/day)                                                          
      \<10^7^                  21      1.07      0.42, 1.73     0.003         0.616
      ≥107                     21      0.97      0.33--1.62     0.001         
  UCB                          62                                             
    Age (years)                                                               
      \<18                     56      −0.14     −1.28, 0.99    0.327         0.485
      ≥18                      6       0.19      −0.19, 0.57    0.804         
    Dose (IU/kg/day)                                                          
      \<10^7^                  13      −0.20     −0.98, 0.57    0.603         0.005
      ≥107                     49      0.25      −0.15, 0.66    0.217         
    Disease history (months)                                                  
      \<3                      6       0.19      −0.19, 0.57    0.804         0.483
      ≥3                       56      −0.14     −1.28, 0.99    0.327         

SMD refers to comparisons between the pre- and post-SC therapy levels. CI, confidence interval; HSC, hematopoietic stem cells; MSC, mesenchymal stem cells; SMD, standardized mean difference; UCB, umbilical cord blood.

[^1]: Contributed equally
